TNGX
NASDAQ HealthcareTango Therapeutics, Inc. - Common Stock
Biotechnology
Tango Therapeutics, Inc., a precision oncology company, focuses on the discovery and development of drugs in defined patient populations with unmet medical need. The company develops methylthioadenosine -cooperative protein arginine methyltransferase 5 (PRMT5) inhibitors, including TNG462, which is in Phase 1/2 clinical trial for treating pancreatic and lung cancer; and TNG456, a brain-penetrant PRMT5 inhibitor for the treatment of glioblastoma. It is developing TNG260, a co-repressor of repressor element-1 silencing transcription inhibitor to reverse the immune evasion effect of serine-threonine kinase (STK) 11 loss-of-function mutations to treat lung cancer. The company was founded in 2017 and is headquartered in Boston, Massachusetts.
๐ Market Data
| Price | $20.98 |
|---|---|
| Volume | 3,004,728 |
| Market Cap | 3.03B |
| Beta | 1.310 |
| RSI (14-Day) | 48.1 |
| 200-Day MA | $11.42 |
| 50-Day MA | $19.48 |
| 52-Week High | $28.41 |
| 52-Week Low | $1.03 |
| Forward P/E | -12.86 |
| Price / Book | 8.24 |
๐ฏ Investment Strategy Scores
TNGX scores across each investment strategy. Higher is better for that strategy's goals.
๐ Strategy Interpretation
Best fit: ๐ Moon Shot (79/100) โ this strategy High growth potential (high beta + oversold).
Lowest fit among scored strategies: ๐ช Falling Knife (11/100). No single score is a buy or sell signal โ use multiple lenses together. Learn how to read these scores โ
๐ Learn More
Indicators on this page
Educational articles
Find TNGX in your text
Paste any article, transcript, or post โ the tool will extract TNGX and every other hidden ticker.
Disclaimer: This data is for educational and entertainment purposes only and does not constitute financial advice. Market data may be delayed. Always do your own research before making investment decisions.
Data last updated: 2026-05-01.